Objective: We aimed to describe temporal changes in substance use among HIVinfected pregnant women in the United States from 1990 to 2012.
Introduction
Approximately 8700 HIV-infected women give birth in the United States annually [1, 2] . Rates of substance use in this population have historically been high; in the late 1980s and early 1990s, half of HIV-infected pregnant women used illicit substances [3, 4] . Substance use during pregnancy in HIV-infected women has negative implications for transmission [5] [6] [7] [8] , infant outcomes [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , and the health of the mother [20] .
Over time, the route of HIV acquisition among women has changed in the United States. Whereas approximately 50% of female AIDS cases were linked to injection drug use in 1990 [21] , by 2011, it was the suspected source of infection in only 14% of HIV diagnoses among women [22] . However, to our knowledge, no studies have examined substance use patterns in HIV-infected pregnant women over the last two decades.
Using data from two large US-based cohorts, we describe the dramatic decrease in maternal substance use during pregnancy from 1990 to 2012 among HIV-infected women, and explore possible explanations for the decrease.
Methods

Study participants and design
This study included women enrolled in the Women and Infants Transmission Study (WITS) or the Surveillance Monitoring for Antiretroviral Therapy Toxicities (SMARTT) protocol of the Pediatric HIV/AIDS Cohort Study (PHACS). WITS enrolled women who gave birth from 1990 to 2005 [23] , whereas SMARTT is ongoing, with the first delivery occurring in 1995 [24] . In WITS/ SMARTT, written informed consent was obtained from each participating woman, and the institutional review board at each study center approved study protocols.
In WITS, women had multiple study visits during pregnancy. In SMARTT, two groups of women and children (dynamic and static) were enrolled. In the dynamic cohort, women were enrolled during pregnancy through 72 h postdelivery. The static cohort enrolled women with children aged 0-12 years. For both WITS and SMARTT, trained study personnel conducted structured interviews at enrollment to assess demographic characteristics.
Women were eligible for this study if they were enrolled in WITS/SMARTT, gave birth from 1 January 1990 to 31 December 2012, and provided self-reported information on substance use during pregnancy.
Substance use
In WITS, a questionnaire was administered at each predelivery visit to ascertain use of alcohol, tobacco, marijuana, heroin, cocaine, and injected drugs during pregnancy. One urine sample for drug testing was collected at the intake visit and one was collected during labor or immediately postpartum. Urine was screened for cocaine, heroin/opiates, marijuana, alcohol, or their metabolites using a radioimmunoassay followed by confirmatory gas chromatography and mass spectrometry [7] .
Women in dynamic SMARTT completed a substance use interview within 7 days of delivery, and women in static SMARTT completed this interview at time of enrollment [median ¼ 3.7 years after pregnancy, interquartile range (IQR) ¼ 1.8-6.2 years]. In a subsample of the dynamic cohort, meconium -an infant's first stool -was collected and screened for cocaine, heroin/opiates, marijuana, alcohol, tobacco, or their metabolites using an immunoassay technique followed by confirmatory gas chromatography and mass spectrometry [25] .
Women were classified as using a substance if they selfreported or had a positive biological sample for alcohol, tobacco, marijuana, cocaine, or heroin during pregnancy. Polysubstance use was defined as using two or more substances during pregnancy.
Statistical methods
The proportion of women in each substance use category was calculated, stratified by year of delivery. To test whether the proportion of women using substances during pregnancy changed over time while accounting for correlation between repeated pregnancies, we used log binomial generalized estimating equation (GEE) models. As meconium samples were not available for all SMARTT participants, we conducted two sensitivity analyses; the first included only WITS pregnancies, whereas the second also included the SMARTT pregnancies with meconium data.
Multivariable logistic GEE models were constructed to evaluate predictors of substance use in the pre-highly active antiretroviral therapy (HAART) (1990-1995) and HAART (1996-2012) eras. These models included race/ ethnicity, age, education, household income, marital status, HIV diagnosis prior to pregnancy, and antiretroviral therapy regimen.
To evaluate trends within individuals, log binomial GEE models were used in the subset of women with multiple pregnancies under observation in WITS/SMARTT. We compared substance use prevalence in WITS/ SMARTT with use among pregnant women in a nationally representative household survey, the National Survey on Drug Use and Health (NSDUH). In NSDUH, substance use during pregnancy is defined as self-report of past 30-day substance use and being pregnant. We compared WITS/SMARTT and NSDUH beginning in
Results
Of the 5724 pregnancies in WITS/SMARTT, we excluded 233 because self-reported substance use information was unavailable and 40 because delivery year was unknown. Therefore, a total of 5451 pregnancies from 4408 individual women were included in this analysis.
Maternal characteristics for each pregnancy are described in Table 1 .
Nearly 82% of respondents used at least one substance in 1990; this proportion decreased linearly over time until 2006, when it plateaued at approximately 23% ( Fig. 1 ). A similar pattern was observed for each individual substance over the 23-year period. The prevalence of tobacco use decreased from 64.9 to 18.2%; alcohol from 57.4 to 9.3%; marijuana from 25.5 to 6.7%; cocaine from 36.2 to 1.3%; and heroin from 27.7 to 0.0%. The prevalence of injection drug use declined from a peak of 17.1% in 1991 to 0.0%, and polysubstance use fell from 64.9% in 1990 to approximately 10% from 2007 onwards (data not shown). In the pre-HAART and HAART eras, multivariable models showed non-Hispanic white race, older age, less education, and being unmarried were associated with substance use during pregnancy ( Of the 4408 women included in the previous analysis, 824 had multiple pregnancies under study observation. For most substances, the risk of a woman using the substance did not change with successive pregnancies; the association between pregnancy order and use of tobacco, marijuana, cocaine, heroin, any substance, multiple substances, or injected drugs was not statistically significant. Risk of alcohol use was slightly reduced in later pregnancies (RR, 0.91; 95% CI, 0.82-1.00). Of note, women who used a substance in their previous pregnancy had an elevated risk of substance use during their next pregnancy (RR, 5.71; 95% CI, 4.63-7.05).
We compared annual prevalence of alcohol, tobacco, marijuana, cocaine, and heroin use during pregnancy among HIV-infected women in WITS/SMARTT with estimates from NSDUH (see Figures, Supplemental Digital Content 1, http://links.lww.com/QAD/A595). From 1994 to the early 2000s, use of these substances was substantially higher among women in WITS/SMARTT, compared with pregnant women in the general population. However, from the mid-2000s to 2012, prevalence of substance use appears comparable between the two groups.
Discussion
We describe the substantial decline in licit and illicit substance use during pregnancy that occurred between 1990 and 2012 in a population of two US-based cohorts of HIV-infected women. Although the prevalence of substance use was initially considerably higher in WITS/ SMARTT, it has become similar to that of pregnant women in the general US population.
Women who used substances in previous pregnancies had over a five-fold increased risk of using a substance in future pregnancies. Therefore, we posit that the observed decrease in substance use is not due to the cessation of substance use in women who previously used substances, but rather, HIV is affecting a different population of women. It is possible that an epidemiological transition has occurred, in which the types of women becoming infected with HIV in the Unites States has changed. This is supported by data from the Centers for Disease Control and Prevention, which show that the primary route of infection among women has gradually transitioned from injection drug use to heterosexual contact [21, 22] .
We observed that substance use is inversely associated with receiving antiretroviral therapy in pregnant women, consistent with a past study of HIV-infected adults [45] .
Others have reported current injection drug users were less likely than past users to receive antiretroviral therapy [46] , and substance users not enrolled in treatment programmes were less likely to receive antiretroviral therapy than those receiving treatment [47] . Because substance use is inversely associated with antiretroviral therapy and a number of potential outcomes, it may be an important confounder in antiretroviral safety studies, especially those using historical comparison data.
Our study has several limitations. First, our sample may not represent the larger population of HIV-infected women who gave birth from 1990 to 2012. Second, different biological specimens were used to confirm substance use in each cohort. Urine-based and meconium-based tests have varying sensitivity, specificity, and windows of detection [48] [49] [50] . Third, only 22% of women in SMARTT had meconium samples analyzed for substances, and some women in the static SMARTT cohort had long recall periods. However, restricting our analysis to women with available biological assays suggest Any substance use 1 9 9 0 1 9 9 5 2 0 0 0 2 0 0 5 2 0 1 0 that our findings are not explained by recall or social desirability bias. Furthermore, past analyses of the dynamic SMARTT cohort have shown reliable sensitivity and specificity of self-reported substance use compared with biological measures [25] . Fourth, NSDUH's classification of substance use during pregnancy (being pregnant and using a substance in the past month) differs from that of WITS and SMARTT, and was not confirmed by biological assays, meaning data from NSDUH in the Supplemental Digital Content may be underestimated (http://links.lww.com/QAD/A595). Finally, this analysis could not investigate temporal trends in prescription opioids because WITS did not collect the necessary information. However, few women in SMARTT (4.4%) reported medical or nonmedical use of prescription opioids during pregnancy.
This study provides important information about temporal trends in substance use among HIV-infected pregnant women in the United States. We documented a dramatic decrease in prevalence of substance use during pregnancy since 1990, which may be due to a shift in the HIV epidemic among women in the United States. The finding that substance use during pregnancy has historically been associated with lack of antiretroviral use is concerning and may warrant further investigation. Our observation that HIV-infected women who used substances in past pregnancies are at increased risk of use during future pregnancies suggests they may be important to target in efforts to further reduce substance use in this population.
